© 2019 Sulfagenix Inc.

Innovative Solutions to    Serious Health Problems

Sulfagenix, Inc. is built on decades of research on modifying existing molecules to improve safety, bioavailability and efficacy for new uses.
SG1002 (sodium polysulthionate), Sulfagenix’s clinical-stage molecule, is a precursor to a natural-occurring molecule, hydrogen sulfide, for which deficits have been shown to exist in a number of serious diseases, including cardiovascular disease.


To develop novel therapeutic solutions that address unmet medical needs by safely and effectively improving the bioavailability of naturally occurring compounds.